The price of the New Shares will be determined through an accelerated book building procedure. The bookbuilding will begin on July 2, 2014 at 17:40 pm CET.

The Company intends to use the proceeds from the Private Placement to strengthen the working capital as well as finance the continued operations and further development of additional human and veterinary products based on the XR-17 technology.

The Private Placement is subject to, inter alia, a resolution by the Board of Directors of Oasmia, pursuant to the authorization granted by the annual general meeting held on September 30, 2013, to issue New Shares following the completion of the Private Placement book building procedure. The reason for deviating from the shareholders’ preferential rights by conducting a directed new share issue is to broaden the shareholder base and that the costs of the procedure and the timing collectively and with sufficient strength indicate that it is in the Company’s and thus the shareholders’ interest that the issue is made with deviation from the shareholders’ preferential rights.

Carnegie Investment Bank AB (publ) is acting as financial advisor and sole bookrunner.

The information above has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published on July 2, 2014 at 17.30 pm CET.

About Oasmia
Oasmia develops new generations of drugs in the field of human and veterinary oncology. The Company’s product development aims to develop novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The Company’s product development is based on its proprietary in-house research and company patents. Oasmia’s shares, ISIN SE0000722365, are listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX).

Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the constituent information in accordance with the rules and regulations prevailing in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Oasmia Pharmaceutical AB (publ) securities in any jurisdiction, neither from Oasmia Pharmaceutical AB (publ), Carnegie Investment Bank AB (publ) nor anyone else.